This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Bioxcel Therapeutics, Inc. Announces Transquility In-Care Pivotal Phase 3 Trial Plan with Bxcl501 for Agitation Associated with Alzheimer's Dementia CI
BioXcel Therapeutics Prices $25 Million Registered Direct Offering of Shares, Warrants MT
BioXcel Therapeutics Gets European Patent for Method of Treating Agitation in Dementia MT
Canaccord Genuity Cuts Price Target on BioXcel Therapeutics to $7 From $20, Maintains Buy Rating MT
UBS Adjusts BioXcel Therapeutics Price Target to $3.50 From $4, Maintains Neutral Rating MT
Transcript : BioXcel Therapeutics, Inc., Q4 2023 Earnings Call, Mar 12, 2024
BioXcel Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
North American Morning Briefing : Inflation Data -2- DJ
North American Morning Briefing : Nvidia Ignites -2- DJ
UBS Downgrades BioXcel Therapeutics to Neutral From Buy, Cuts Price Target to $4 From $9 MT
BioXcel Therapeutics Shares Soar After Terminating Proposed $60 Million Stock Offering MT
BioXcel Therapeutics' BXCL701 Granted FDA Fast-Track Designation to Treat Small Cell Neuroendocrine Prostrate Cancer MT
BioXcel Therapeutics, Inc. Enter into the Third Amendment to Credit Agreement and Guaranty CI
BioXcel Therapeutics Shares Rise Premarket on FDA Fast-Track Designation DJ
BioXcel Therapeutics, Inc. Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer CI
Top Midday Decliners MT
BioXcel Therapeutics Starts $60 Million Public Offering; Shares Drop MT
Wall Street Set to Open Modestly Higher as S&P Hovers Just Above 5,000 MT
Positive Quarterly Earnings Boost Exchange-Traded Funds, Equity Futures Pre-Bell Friday MT
US Futures Nudge Higher as S&P Remains Just Above 5,000 MT
Top Premarket Decliners MT
BioXcel Therapeutics, Inc. Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of Bxcl701 in Combination with Keytruda® CI
BioXcel Therapeutics, Inc. Announces USPTO's Allowance of Patent Application for Method of Treating Agitation in Alzheimer's Disease Using Oromucosal Formulations of Dexmedetomidine CI
Transcript : BioXcel Therapeutics, Inc. - Special Call
BioXcel Therapeutics Names Vincent J. O'Neill Chief of Product Development MT
Chart BioXcel Therapeutics, Inc.
More charts
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
2.9 USD
Average target price
7.417 USD
Spread / Average Target